Biowaiver monographs for immediate release solid oral dosage forms: rifampicin.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmacy and Science

• Publication date

  2009-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jps.21624PMID 19160441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

  2015cited by this paper
• Committee for Proprietary Medicinal Products (CPMP)

  2009cited by this paper
• European Medicines Evaluation Agency (EMEA)

  2009cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium.

  2009cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: pyrazinamide.

  2008cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: metoclopramide hydrochloride.

  2008cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: acetazolamide.

  2008cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride.

  2008cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: aciclovir.

  2008cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: isoniazid.

  2007cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: prednisone.

  2007cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: prednisolone.

  2007cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol).

  2006cited by this paper
• Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection—United States, 2003

  2006cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: cimetidine.

  2006cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride.

  2006cited by this paper
• Spectrophotometric determination of rifampicin through chelate formation and charge transfer complexation in pharmaceutical preparation and biological fluids.

  2006cited by this paper
• Spectrophotometric Determination of Rifampicin through Chelate Formation and Charge Transfer Complexation in Pharmaceutical Preparation and Biological Fluids

  2006cited by this paper
• Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms

  2005cited by this paper
• Toman's tuberculosis: case detection, treatment, and monitoring.

  2005cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.

  2005cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride.

  2005cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride.

  2005cited by this paper
• Monitoring and management of antituberculosis drug induced hepatotoxicity

  2005cited by this paper
• Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities.

  2005cited by this paper
• Evidence of efflux-mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques.

  2004cited by this paper
• Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.

  2004cited by this paper
• Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease

  2004cited by this paper
• In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after real time storage at ambient conditions.

  2004cited by this paper
• Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.

  2004cited by this paper
• Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.

  2004cited by this paper
• Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System

  2004cited by this paper
• Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.

  2004cited by this paper
• Solid-state characterization of rifampicin samples and its biopharmaceutic relevance.

  2004cited by this paper
• Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin.

  2004influential reference
• Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.

  2004cited by this paper
• Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.

  2003cited by this paper
• In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations.

  2003cited by this paper
• Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and the presence of light. Part III: Various drug substances and excipients

  2003cited by this paper
• Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.

  2003cited by this paper
• Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

  2002cited by this paper
• Anions complexes du chrome en analyse et le controle des medicaments. determination de la rifampicine

  2002cited by this paper
• Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.

  2002cited by this paper
• Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

  2002cited by this paper
• Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and the presence of light. 1. Pure anti-tuberculosis drugs and their combinations.

  2002cited by this paper
• Studies on rifampicin release from ethylcellulose coated nonpareil beads.

  2002cited by this paper
• Characterization of the Solubility and Dissolution Properties of Several New Rifampicin Polymorphs, Solvates, and Hydrates

  2001cited by this paper
• [Immuno-allergic accidents with rifamipcin].

  2001cited by this paper
• Stability of rifampicin in dissolution medium.

  2000cited by this paper
• Serious side effects of rifampin on the course of WHO/MDT: a case report.

  2000cited by this paper
• Stability of rifampicin in dissolution medium.

  2000cited by this paper
• Solubility and Dissolution Properties of Generic Rifampicin Raw Materials

  2000influential reference
• Pharmacokinetic Factors in the Modern Drug Treatment of Tuberculosis

  1999cited by this paper
• Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.

  1999cited by this paper
• Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

  1999cited by this paper
• Stability of rifampicin in dissolution medium in presence of isoniazid.

  1999cited by this paper
• Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.

  1999cited by this paper
• Comparative bioavailability of three different preparations of rifampicin

  1999cited by this paper
• Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics.

  1999influential reference
• Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing.

  1998cited by this paper
• The Merck index

  1998cited by this paper
• When Are Bioavailability Studies Required? A German Proposal

  1998cited by this paper
• Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.

  1997cited by this paper
• Intestinal Drug Absorption and Metabolism in Cell Cultures: Caco-2 and Beyond

  1997cited by this paper
• In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth

  1997cited by this paper
• Low Antituberculosis Drug Concentrations in Patients with AIDS

  1996cited by this paper
• P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

  1996cited by this paper
• Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

  1996cited by this paper
• Helicobacter pylori, gastric acid, and duodenal gastric metaplasia.

  1996cited by this paper
• Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man

  1995cited by this paper
• Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.

  1995cited by this paper
• Bioinequivalence and Drug Toxicity

  1994cited by this paper
• Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

  1993cited by this paper
• Malabsorption of antituberculosis medications by a patient with AIDS.

  1992cited by this paper
• Analytical profiles of drug substances and excipients

  1992cited by this paper
• Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

  1991cited by this paper
• Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells.

  1990cited by this paper
• Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

  1990cited by this paper
• A Review of the Redman Syndrome and Rifampicin Overdosage

  1989cited by this paper
• Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy

  1989cited by this paper
• Rifampicin raw material characteristics and their effect on bioavailability.

  1989cited by this paper
• Influence of the enzyme induction by rifampicin on its presystemic metabolism.

  1987cited by this paper
• Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion.

  1986cited by this paper
• Pharmacokinetics of rifampin in children. II. Oral bioavailability.

  1986cited by this paper
• Pharmacokinetics of oral and intravenous rifampicin during chronic administration

  1985cited by this paper
• Clinical Pharmacokinetics of the Antituberculosis Drugs

  1984cited by this paper
• Effect of antacids on oral absorption of rifampicin

  1984cited by this paper
• Effect of Food on Bioavailability of Rifampicin

  1983cited by this paper
• Bioavailability of rifampicin capsules.

  1983influential reference
• Pharmacokinetic studies of rifampicin in the elderly.

  1983cited by this paper
• Clinical Pharmacokinetics of Rifampicin

  1978influential reference
• The renal elimination of rifampicin as a function of the oral dose. A convenient way to assess relative bioavailability.

  1978cited by this paper
• Polymorphism of rifampicin.

  1977cited by this paper
• Serum and urine concentrations of rifampicin administered by intravenous infusion in man.

  1977cited by this paper
• Absorption of rifampin from various preparations and pharmaceutic forms

  1977cited by this paper
• Pharmacokinetic study of intravenous rifampicin.

  1977cited by this paper
• BLOOD-LEAD AND DOMESTIC-WATER LEAD

  1976cited by this paper
• Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite

  1975influential reference
• The use of rifampicin in the treatment of leprosy.

  1975cited by this paper
• The use of rifampicin in the treatment of leprosy.

  1975cited by this paper

• Removal of Rifampicin and Rifaximin Antibiotics on PET Fibers: Optimization, Modeling, and Mechanism Insight

  2025cites this paper
• Predicting Food Effect On Oral Drug Absorption For Solubility-Epithelial Membrane Permeation-Limited Cases With Bile Micelle Solubilization

  2025influential citation
• In vitro biopharmaceutical equivalence of drugs used in the treatment of tuberculosis in Peru

  2025cites this paper
• Serosal nodules and orange peritoneal dialysis effluent.

  2025cites this paper
• Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (iBCS).

  2024cites this paper
• The Development of an Age-Appropriate Fixed Dose Combination for Tuberculosis Using Physiologically-Based Pharmacokinetic Modeling (PBBM) and Risk Assessment

  2024cites this paper
• Coupling Drug Dissolution with BCS

  2024cites this paper
• Physicochemical interaction of rifampicin and ritonavir-lopinavir solid dispersion: an in-vitro and ex-vivo investigation

  2024cites this paper
• Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers

  2024cites this paper
• Eutectic solutions for healing: a comprehensive review on therapeutic deep eutectic solvents (TheDES)

  2024cites this paper
• Biowaiver based on biopharmaceutics classification system: Considerations and requirements

  2023cites this paper
• Lipid-based particle engineering via spray-drying for targeted delivery of antibiotics to the lung.

  2023cites this paper
• In vitro optimization of crushed drug-sensitive antituberculosis medication when administered via a nasogastric tube

  2023cites this paper
• In vitro, in-vivo, and in-silico investigation of physicochemical interactions between pioglitazone and rifampicin.

  2023cites this paper
• Drug-in-cyclodextrin-in-polymeric nanoparticles: A promising strategy for rifampicin administration.

  2022cites this paper
• A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV [version 1; peer review: 2 approved with reservations]

  2022cites this paper
• The Application of Different Technologies for Removal of Rifampicin From Aquatic Environments: A Recent Review

  2022cites this paper
• Biopharmaceutics studies applied to goyazensolide: a drug candidate from Lychnophora species.

  2022cites this paper
• Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis [version 2; peer review: 2 approved with reservations]

  2022cites this paper
• Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis

  2022cites this paper
• Nanoparticle-Based Rifampicin Delivery System Development

  2021cites this paper
• Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries

  2021cites this paper
• Formulation and bioequivalence testing of fixed-dose combination orally disintegrating tablets for the treatment of tuberculosis in paediatric population.

  2020cites this paper
• Multi-Methodological Quantitative Taste Assessment of Anti-Tuberculosis Drugs to Support the Development of Palatable Paediatric Dosage Forms

  2020cites this paper
• Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis.

  2020cites this paper
• Comparison between Branded and Generic Furosemide 40 mg Tablets Using Thermal Gravimetric Analysis and Fourier Transform Infrared Spectroscopy

  2020cites this paper
• Rifampicin: biotransformation study using the fungus Cunninghamella elegans and monitoring through UHPLC-MS

  2020cites this paper
• Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership—Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis

  2020cites this paper
• Rifampin Stability and Solution Concentration Enhancement Through Amorphous Solid Dispersion in Cellulose ω-Carboxyalkanoate Matrices.

  2018cites this paper
• Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Mycobacterium tuberculosis H37Rv strain

  2018cites this paper
• Crystalline structure of the marketed form of Rifampicin: a case of conformational and charge transfer polymorphism

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 246 Mechanism-based modeling of biological processes involved in oral absorption

  2018cites this paper
• Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.

  2018cites this paper
• Preparation of Pyrazinamide Eutectics versus Cocrystals Based on Supramolecular Synthon Variations

  2018cites this paper
• Validation of a simple isocratic HPLC-UV method for rifampicin and isoniazid quantification in human plasma

  2018cites this paper
• Orally disintegrating tablets: formulation development, novel engineering solutions and fixed dose combinations

  2017cites this paper
• Formulation and Assessment of Taste Masked Combination Therapies for the Treatment of Paediatric Tuberculosis

  2017cites this paper
• Very fast dissolving acid carboxymethylcellulose‐rifampicin matrix: Development and solid‐state characterization

  2017influential citation
• Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

  2016cites this paper
• Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.

  2016cites this paper
• Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2016cites this paper
• and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2016cites this paper
• PREPARATION AND EVALUATION OF RIFAMPICIN-ASCORBIC ACID LOADED PLGA NANOPARTICLES

  2016cites this paper
• Biowaiver monograph for ascorbic acid immediate release solid oral dosage forms

  2016influential citation
• Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2016cites this paper
• Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs

  2016cites this paper
• Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring

  2016cites this paper
• The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity

  2016cites this paper
• Uniform and amorphous rifampicin microspheres obtained by freezing induced LLPS during lyophilization.

  2015influential citation
• University of Groningen Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry Sturkenboom,

  2015cites this paper
• Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis

  2015cites this paper
• Solubility and Distribution of Salinazid and Vanillin Isoniazid in the Solvents Modeling Biological Media

  2015cites this paper
• Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry

  2015cites this paper
• UvA-DARE ( Digital Academic Repository ) Quantification of isoniazid , pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry

  2015cites this paper
• Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer.

  2015cites this paper
• Development and Validation of High-Performance Thin-Layer Chromatographic Method for the Simultaneous Determination of Rifampicin, Isoniazid, and Pyrazinamide in a Fixed Dosage Combination Tablet

  2014cites this paper
• Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers

  2014cites this paper
• Adjusted Indirect Treatment Comparison of the Bioavailability of WHO‐Prequalified First‐Line Generic Antituberculosis Medicines

  2014cites this paper
• The impact of the EMA change in definition of "dose" on the BCS dose-solubility ratio: a review of the biowaiver monographs.

  2014cites this paper
• Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.

  2014cites this paper
• The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.

  2014cites this paper
• Structural characterization of form I of anhydrous rifampicin

  2014cites this paper
• Preparation of rifampicin/poly(d,l-lactice) nanoparticles for sustained release by supercritical assisted atomization technique

  2014cites this paper
• A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin.

  2013influential citation
• Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis

  2013cites this paper
• In Vitro Release Kinetics of Antituberculosis Drugs from Nanoparticles Assessed Using a Modified Dissolution Apparatus

  2013cites this paper
• COMPARATIVE PHARMACOKINETICS OF RIFAMPICIN AND 25-DESACETYL RIFAMPICIN IN HEALTHY VOLUNTEERS AFTER SINGLE ORAL DOSE ADMINISTRATION

  2013cites this paper
• BCS BASED BIOWAIVERS AND THEIR CURRENT REGULATORY ISSUES

  2013cites this paper
• Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery

  2013cites this paper
• Interaction of an Antituberculosis Drug with Nano‐sized Cationic Micelle: Förster Resonance Energy Transfer from Dansyl to Rifampicin in the Microenvironment

  2012cites this paper
• Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate.

  2012cites this paper
• Cryoprotection–lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles

  2012cites this paper
• Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting.

  2012cites this paper
• Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS

  2012cites this paper
• Preparation of sustained release rifampicin microparticles for inhalation

  2012cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride.

  2011cites this paper
• A new respirable form of rifampicin.

  2011cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride.

  2011cites this paper
• Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles.

  2010cites this paper
• Stability of anti–tuberculosis actives in the PheroidTM delivery system

  2010influential citation
• Biowaiver monographs for immediate release solid oral dosage forms: Doxycycline hyclate.

  2010influential citation
• Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.

  2010cites this paper
• Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

  2010cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: furosemide.

  2010cites this paper
• FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Fármaco e Medicamentos Área de Produção e Controle Farmacêuticos Sistema de Classificação Biofarmacêutica e Bioisenções

  2009cites this paper